Literature DB >> 18842713

The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.

Alexander Bukreyev1, Lijuan Yang, Jens Fricke, Lily Cheng, Jerrold M Ward, Brian R Murphy, Peter L Collins.   

Abstract

Respiratory syncytial virus (RSV) readily infects and reinfects during infancy and throughout life, despite maternal antibodies and immunity from prior infection and without the need for significant antigenic change. RSV has two neutralization antigens, the F and G virion glycoproteins. G is expressed in both membrane-bound (mG) and secreted (sG) forms. We investigated whether sG might act as a decoy for neutralizing antibodies by comparing the in vitro neutralization of wild-type (wt) RSV versus recombinant mG RSV expressing only mG. wt RSV indeed was less susceptible than mG RSV to monovalent G-specific and polyvalent RSV-specific antibodies, whereas susceptibility to F-specific antibodies was equivalent. This difference disappeared when the virus preparations were purified to remove sG. Thus, sG appears to function as a neutralization decoy. We evaluated this effect in vivo in mice by comparing the effects of passively transferred antibodies on the pulmonary replication of wt RSV versus mG RSV. Again, wt RSV was less sensitive than mG RSV to G-specific and RSV-specific antibodies; however, a similar difference was also observed with F-specific antibodies. This confirmed that sG helps wt RSV evade the antibody-dependent restriction of replication but indicated that in mice, it is not acting primarily as a decoy for G-specific antibodies, perhaps because sG is produced in insufficient quantities in this poorly permissive animal. Rather, we found that the greater sensitivity of mG versus wt RSV to the antiviral effect of passively transferred RSV antibodies required the presence of inflammatory cells in the lung and was Fc gamma receptor dependent. Thus, sG helps RSV escape the antibody-dependent restriction of replication via effects as an antigen decoy and as a modulator of leukocytes bearing Fc gamma receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842713      PMCID: PMC2593351          DOI: 10.1128/JVI.01604-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus.

Authors:  R Ray; D F Hoft; K Meyer; R Brown; L M Lagging; R B Belshe
Journal:  Virus Res       Date:  2001-06       Impact factor: 3.303

2.  Genetic diversity and molecular epidemiology of the G protein of subgroups A and B of respiratory syncytial viruses isolated over 9 consecutive epidemics in Korea.

Authors:  E H Choi; H J Lee
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.

Authors:  M N Teng; S S Whitehead; P L Collins
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

4.  The effect of dexamethasone on body and organ growth of normal and IGF-II-transgenic mice.

Authors:  R Rooman; G Koster; R Bloemen; R Gresnigt; S C van Buul-Offers
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

5.  Glucocorticoid administration accelerates mortality of pneumovirus-infected mice.

Authors:  J B Domachowske; C A Bonville; D Ali-Ahmad; K D Dyer; A J Easton; H F Rosenberg
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

6.  Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Authors:  P F Wright; R A Karron; R B Belshe; J Thompson; J E Crowe; T G Boyce; L L Halburnt; G W Reed; S S Whitehead; E L Anderson; A E Wittek; R Casey; M Eichelberger; B Thumar; V B Randolph; S A Udem; R M Chanock; B R Murphy
Journal:  J Infect Dis       Date:  2000-09-22       Impact factor: 5.226

7.  Epitopes involved in antibody-mediated protection from Ebola virus.

Authors:  J A Wilson; M Hevey; R Bakken; S Guest; M Bray; A L Schmaljohn; M K Hart
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

8.  Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein.

Authors:  J Schwarze; U Schauer
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

Review 9.  Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion.

Authors:  Edward S Mocarski
Journal:  Trends Microbiol       Date:  2002-07       Impact factor: 17.079

Review 10.  Viral mimicry of cytokines, chemokines and their receptors.

Authors:  Antonio Alcami
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

View more
  77 in total

1.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

Review 2.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

3.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

Review 4.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

5.  Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Authors:  S Boyoglu-Barnum; S O Todd; J Meng; T R Barnum; T Chirkova; L M Haynes; S J Jadhao; R A Tripp; A G Oomens; M L Moore; L J Anderson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 6.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

7.  Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects.

Authors:  Luis M Branco; Jessica N Grove; Lina M Moses; Augustine Goba; Mohammed Fullah; Mambu Momoh; Randal J Schoepp; Daniel G Bausch; Robert F Garry
Journal:  Virol J       Date:  2010-11-09       Impact factor: 4.099

Review 8.  Structure and function of respiratory syncytial virus surface glycoproteins.

Authors:  Jason S McLellan; William C Ray; Mark E Peeples
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.

Authors:  Peter L Collins; Rachel Fearns; Barney S Graham
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.